HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Antonelli, A. Articles by Serio, M. Search for Related Content PubMed PubMed Citation Articles by Antonelli, A. Articles by Serio, M.

Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process

Metabolism Unit, Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa-School of Medicine, Via Roma, 67, I-56100, Pisa, Italy, ¹ Department of Clinical and Experimental Medicine and Surgery ‘F. Magrassi-A. Lanzara’, Second University of Naples, Naples, Italy, ² Department of Clinical Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy and ³ Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy

(Correspondence should be addressed to A Antonelli; Email: a.antonelli{at}med.unipi.it)

Objective: Serum CXCL10 (an interferon--inducible chemokine) levels (sCXCL10) are increased in several autoimmune conditions, including Graves’ disease (GD) and autoimmune thyroiditis (AT). Longitudinal assessment of sCXCL10 in autoimmune hypo- or hyperthyroidism has not yet been performed.

Design and methods: We longitudinally assayed sCXCL10 in the following groups:

1. thirty-three GD and 11 toxic nodular goiter (TNG) patients when hyperthyroid (Hyper) and when reaching euthyroidism (Eu) with methimazole therapy (MMI)
   
2. sixty-six AT (33 hypothyroid (Hypo) and 33 Eu) patients, basally and after reaching EU (for Hypo) with levothyroxine (L-T₄) therapy
   
3. twenty-two patients with thyroid cancer (CA) under L-T₄-suppressive treatment, of whom 11 were re-evaluated after L-T₄ withdrawal for diagnostic WBS, and 11 after recombinant TSH (rhTSH) administration
   
4. thirty-three healthy controls.
   

Results: At initial evaluation, Hyper GD and AT (Hypo significantly higher than Eu) showed significantly higher mean sCXCL10 than all other groups. MMI treatment led to a significant decrease in sCXCL10 only in GD (not in TNG), while restoration of Eu, in Hypo AT, by L-T₄ was not accompanied by significant sCXCL10 change. CA showed sCXCL10 comparable to controls, and both Hypo after L-T₄ withdrawal and rhTSH injection had no effect on sCXCL10.

Conclusions: Treatment of Hyper leads to a significant decrease in sCXCL10 only in GD, and this probably depends upon the MMI immunomodulatory effect. L-T₄ correction of Hypo is not accompanied by significant modification of sCXCL10 in AT. Increased sCXCL10 is not associated with Hyper or Hypo per se, but is specifically sustained by the autoimmune inflammatory event occurring in both GD and AT.

This article has been cited by other articles:

				E. Borgogni, E. Sarchielli, M. Sottili, V. Santarlasci, L. Cosmi, S. Gelmini, A. Lombardi, G. Cantini, G. Perigli, M. Luconi, et al. Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells Endocrinology, July 1, 2008; 149(7): 3626 - 3634. [Abstract] [Full Text] [PDF]

				A. Antonelli, C. Ferri, P. Fallahi, S. M. Ferrari, D. Giuggioli, M. Colaci, A. Manfredi, S. Frascerra, F. Franzoni, F. Galetta, et al. CXCL10 ({alpha}) and CCL2 ( ) chemokines in systemic sclerosis a longitudinal study Rheumatology, January 1, 2008; 47(1): 45 - 49. [Abstract] [Full Text] [PDF]

				C Crescioli, L Cosmi, E Borgogni, V Santarlasci, S Gelmini, M Sottili, E Sarchielli, B Mazzinghi, M Francalanci, A Pezzatini, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes J. Endocrinol., October 1, 2007; 195(1): 145 - 155. [Abstract] [Full Text] [PDF]

				M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani Role of Chemokines in Endocrine Autoimmune Diseases Endocr. Rev., August 1, 2007; 28(5): 492 - 520. [Abstract] [Full Text] [PDF]

				Y. Inukai, A. Momobayashi, N. Sugawara, and Y. Aso Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease Eur. J. Endocrinol., June 1, 2007; 156(6): 623 - 630. [Abstract] [Full Text] [PDF]